Loading
A phase 2 trial of GR1803 in multiple myeloma, run by Genrix (Shanghai) Biopharmaceutical Co., Ltd., active and no longer recruiting.
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06566547 by Genrix (Shanghai) Biopharmaceutical Co., Ltd., with 116 participants planned, started 2024-08-26 and due to reach its primary completion in 2027-05-12. Interventions recorded: GR1803 injection. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Genrix Bio, GR1803, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/